BioXcel Therapeutics, Inc. 

555 Long Wharf Drive 

New Haven, CT 06511

 

November 13, 2023

 

VIA EDGAR TRANSMISSION

 

Securities and Exchange Commission 

Division of Corporation Finance 

Office of Life Sciences 

100 F Street, N.E. 

Washington, DC 20549 

Attention: Joshua Gorsky

 

Re:         BioXcel Therapeutics, Inc. 

Registration Statement on Form S-3 

File No. 333-275261

 

To the addressee set forth above:

 

BioXcel Therapeutics, Inc. (the “Company”) hereby respectfully requests the withdrawal of its acceleration request letter filed as correspondence via EDGAR transmission on November 9, 2023, which requested that the Registration Statement on Form S-3 (File No. 333-275261) filed on November 2, 2023 become effective on Tuesday, November 14, 2023, at 9:00 a.m., Washington D.C. time, or as soon as reasonably practicable thereafter. The Company is no longer requesting that such Registration Statement be declared effective at this specific date and time and the Company hereby formally withdraws its request for acceleration of the effective date as stated above.

 

Furthermore, in accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the Company hereby requests the acceleration of the effective date of the Registration Statement on Form S-3 (File No. 333-275261) filed on November 2, 2023, so that it will become effective on November 13, 2023, at 4:30 p.m., Washington D.C. time, or as soon thereafter as practicable, or at such later time as the Company or its counsel may request via telephone call to the staff.

 

The Company requests that we be notified of such effectiveness by a telephone call to Keith L. Halverstam of Latham & Watkins LLP at (212) 906-1761 or N. Danny Shulman at (212) 906-4510 and that such effectiveness also be confirmed in writing.

 

	Very truly yours,
	BioXcel Therapeutics, Inc.
	By:	/s/ Richard Steinhart
		Richard Steinhart
		Chief Financial Officer

 

cc:

Keith L. Halverstam, Latham & Watkins LLP

N. Danny Shulman, Latham & Watkins LLP